The real distribution of microbiota along the colonic mucosa using a novel device capable of taking *protected* biopsies
Completed
- Conditions
- niet van toepassing10017943
- Registration Number
- NL-OMON38135
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Boston scale <3 during colonoscopy
Sufficient indication to perform colonoscopy again
Exclusion Criteria
• Inability to give informed consent
• Life expectancy < 12 months
• Use of combination of two platelet aggregation inhibitors
• Mandatory use of anti-coagulatory medication
• Known history of hemostatic disorder
•Use of systemic antibiotics in preceding 6 weeks
•Use of probiotic or prebiotic treatment in preceding 6 weeks
•Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli)
• History of surgery:
oResection of any part of the colon or Ileocoecal resection
oPresence of an ileo- or colostoma
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Intra-individual differences in phylogenetic fingerprinting and phylotype<br /><br>quantification from mucosal and faecal biopsy samples located at the colon<br /><br>ascendens and the sigmoid both in an *ill prepared* as well as in a *well-<br /><br>prepared* situation</p><br>
- Secondary Outcome Measures
Name Time Method <p>• Intra-individual differences in phylogenetic fingerprinting and phylotype<br /><br>quantification from mucosal and fecal biopsy samples located at the colon<br /><br>ascendens and sigmoid using *protected* biopsy material versus *un-protected*<br /><br>material.</p><br>